Loading...

DexCom, Inc.

DXCMNASDAQ
HealthcareMedical - Devices
$86.67
$0.93(1.08%)

DexCom, Inc. (DXCM) Stock Overview

Explore DexCom, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
11.34%
11.34%
Profit Growth
$1.37
6.41%
EPS Growth
$1.37
1.39%
Operating Margin
15.25%
0.38%
ROE
24.38%
6.41%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
8
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$89.00
Average$114.89
High$145.00

Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CEO

Mr. Kevin Ronald Sayer

Employees

10,200

Headquarters

6340 Sequence Drive, San Diego, CA

Founded

2005

Frequently Asked Questions